AI Therapeutics is pointing to new phase 2a data in 15 patients with a form of amyotrophic lateral sclerosis (ALS), saying the results show promise.
The data provide “early clinical evidence of AIT-101’s ability to clear the toxic protein aggregates that may contribute to the adverse pathology of ALS and provides a strong rationale for further clinical studies,” said Murat Gunel, M.D., professor of genetics and neuroscience at Yale University as well as a member of AI’s scientific advisory board.